Immunology

      Rheumatology Round-Up with Drs. Kavanaugh & Cush
      4 years 11 months ago

      The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.

      RT @SituationRheum: 📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future

      👉close surveillance ➡️ early det

      Elizabeth Graef SituationRheum

      4 years 11 months ago
      📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future 👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity #ACRAmbassador https://t.co/AM2mfYmAtI
      RT @uptoTate: "The goal of a vaccine is not just to protect a (vaccinated) individual, but to end the pandemic." Dr. Dan

      Dr. Rachel Tate uptoTate

      4 years 11 months ago
      "The goal of a vaccine is not just to protect a (vaccinated) individual, but to end the pandemic." Dr. Dan Barouch #ACR20 @RheumNow
      RT @RADoctor: Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 2

      Jeffrey Curtis RADoctor

      4 years 11 months ago
      Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
      RT @AdamJBrownMD: Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically dive

      Adam J Brown AdamJBrownMD

      4 years 11 months ago
      Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically diverse disease. Such an exciting strategy to identify additional unknown diseases!!! #ACR https://t.co/gU9HEZyjRP
      What's New in Calcium Pyrophosphate Disease? with Dr. Michael Pillinger
      4 years 11 months ago

      NYU's Dr. Pillinger talks about Dr. Ann Rosenthal's state of the art talk on calcium pyrophosphate disease at ACR 2020.

      RT @DrMiniDey: Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis pati

      Mrinalini Dey DrMiniDey

      4 years 11 months ago
      Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors - Most RA pts on JAKi have sufficient antibody response to HZ vaccine - Acceptable safety profile Abs#1997 #ACR20 @RheumNow https://t.co/8HWAIwOATD
      RT @drdavidliew: Just a reminder:
      inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhi

      David Liew drdavidliew

      4 years 11 months ago
      Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/qdEpNpzdNs
      RT @RichardPAConway: Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients tre

      Richard Conway RichardPAConway

      4 years 11 months ago
      Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0
      RT @RichardPAConway: Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons

      Richard Conway RichardPAConway

      4 years 11 months ago
      Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons. No significant differences in rates between tofa, ADA, MTX, and placebo. @rheumnow #ACR20 Abstr#L04 https://t.co/8RrG0I2Zwm
      RT @MeralElRamahiMD: Retrosp study in France compared MRIs of 96 pts w/ SpA (65% w/ IBP) vs 104 w/o (25% w/ IBP):
      - 65%

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 11 months ago
      Retrosp study in France compared MRIs of 96 pts w/ SpA (65% w/ IBP) vs 104 w/o (25% w/ IBP): - 65% of pts w/ SpA had bone marrow edema (BME) mainly in the iliac quad of intermed middle segment - 20% w/o SpA had BME mainly in antero-middle quad. #Abst1535 #ACR2020 @RheumNow https://t.co/1ptGGUbUS4
      RT @RHEUMarampa: How often do you perform NFC in suspected SSc patients? @RheumNow #ACR20

      sheila RHEUMarampa

      4 years 11 months ago
      How often do you perform NFC in suspected SSc patients? @RheumNow #ACR20
      RT @drdavidliew: Our RA patients are susceptible to a dangerous virus which runs rampant, but won't take the vaccine.

      W

      David Liew drdavidliew

      4 years 11 months ago
      Our RA patients are susceptible to a dangerous virus which runs rampant, but won't take the vaccine. Why won't patients have their flu shot? @McGillMed 40% hesitant despite public funding. Multiple levels influence; if we don't address, our pts suffer! #ACR20 ABST1740 @RheumNow https://t.co/1Yhr6I2L30
      ABCs of RA: Panel Discussion with Dr. Jonathan Kay
      4 years 11 months ago

      They're back: from Dublin, Melbourne, Boston, Baltimore and Quezon City, Philippines to discuss top abstracts in the area of RA at the end of day three (Sunday) at ACR 2020, led by Dr. Jonathan Kay. Panelists: Dr. Sheila Reyes, Dr. David Liew, Dr. Eric Dein and Dr. Richard Conway.

      RT @uptoTate: I just reviewed the #ACR20 talk regarding vaccination. Highly recommended/timely given data released from

      Dr. Rachel Tate uptoTate

      4 years 11 months ago
      I just reviewed the #ACR20 talk regarding vaccination. Highly recommended/timely given data released from Pfizer today regarding the COVID-19 vaccine trial. ⁦@RheumNow⁩ Pfizer’s Early Data Shows Vaccine Is More Than 90% Effective - The New York Times https://t.co/Fb5ZepCBeJ

      Catch up on Conference Podcasts

      ×